Raptiva (efalizumab) / Roche, EMD Serono, Xoma - LARVOL DELTA

Characteristics, Management, and Outcomes of Latent Tuberculosis Reactivation Following the Use of Biologics for Psoriasis: A Systematic Review (EADV 2025) - "Other biologics included etanercept (20.6%, 7/34), infliximab (17.6%, 6/34), secukinumab (14.7%, 5/34), ustekinumab (8.8%, 3/34), ixekizumab (2.9%, 1/34), and guselkumab (2.9%, 1/34). Two cases used combination therapies, involving etanercept with efalizumab (2.9%, 1/34) and etanercept with adalimumab (2.9%, 1/34)... This systematic review underscores that while biologics are effective and generally safe for psoriasis treatment, latent TB reactivation remains a significant clinical concern. Reactivation was most frequently associated with TNF- α inhibitors but also occurred with IL-17, IL-23, and IL-12/23 inhibitors, likely due to their disruption of immune pathways critical for TB control. Although the RIPE regimen was effective in resolving most cases, psoriasis relapse during treatment highlights the need for integrated, individualized management approaches."

Review • Dermatology • Immunology • Infectious Disease • Ocular Inflammation • Ophthalmology • Psoriasis • Respiratory Diseases • Tuberculosis • Uveitis • Vasculitis • IL12A • IL17A • IL23A

Management of Erythrodermic Psoriasis with Systemic Therapies: A Systematic Review. (PubMed, Am J Clin Dermatol) - "Non-biologic systemic drugs appear to be a rational first-line therapy, with cyclosporine showing good results in managing the acute phase and methotrexate being effective in maintaining remission. In the case of contraindications or treatment failure of traditional systemic therapies, among biologic drugs, the rapidity of action, safety, and limited evidence of efficacy are in favor of IL-17 inhibitors and risankizumab. However, the findings we report are limited by the evidence available in current literature, which is characterized by low statistical power."

Journal • Review • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Fatigue • Hematological Malignancies • Immunology • Lymphoma • Musculoskeletal Pain • Oncology • Psoriasis • IL17A • IL23A

Emerging Therapies for Erosive Oral Lichen Planus: A Systematic Review of Biologics and Small Molecule Inhibitors (EADV 2025) - "The biologics and small molecule inhibitors evaluated across the studies included deucravacitinib, tofacitinib, upadacitinib, roflumilast, tildrakizumab, ustekinumab, secukinumab, guselkumab, rituximab, bevacizumab, apremilast, basiliximab, and efalizumab. Emerging biologic and small molecule therapies demonstrate promise in managing erosive OLP, especially in treatment-resistant cases. However, current evidence is limited to small studies and case reports. Further randomized controlled trials are necessary to establish efficacy, safety, and long-term outcomes."

Review • Dermatology • Dermatopathology • Lichen Planus

Biologic Agents In Systemic Dermatotherapy: Cutaneous And Systemic Side Effects. (PubMed, Curr Drug Saf) - "The purpose of the present article is to review the cutaneous and systemic side effects of all systemic biologic agents used so far in modern treatment of non-malignant skin disorders and to contribute to a better and updated awareness of their safety risks among clinicians, which will enable the latter to make the best informed and personalized drug selection and therapeutic decisions. This review was mainly based on data derived from Medline and Scopus databases and from manufacturing companies, as well."

Journal • Dermatology • Oncology • Psoriasis • Skin Cancer

Biologics for the treatment of alopecia areata: A comprehensive review of clinical trials (SID 2025) - "Studies examining Dupilumab, Secukinumab, Tralokinumab, Abatacept, Alefacept, Efalizumab, and Aldesleukin were identified. Biologics offer a favorable safety profile and hold potential as therapeutic options for AA, although response rates remain inconsistent. Further research is needed to optimize these therapies, identify more effective targets, and determine predictors of clinical response."

Clinical • Review • Alopecia • Immunology • CTLA4 • IL12A • IL13 • IL2 • IL23A

Drug-induced guillain-barré syndrome: a disproportionality analysis based on the US FDA adverse event reporting system. (PubMed, Expert Opin Drug Saf) - "Drugs like brentuximab vedotin and efalizumab showed strong associations with GBS occurrences. This study highlights the importance of monitoring for GBS symptoms following the administration of certain medications, particularly those that affect immune function, and underscores the need for healthcare providers to be aware of the potential neurological risks associated with these medications."

Adverse events • Journal • CNS Disorders • Infectious Disease • Pain

Biologics in lichen planus: A systematic review (AAD 2025) - "Adalimumab was most frequently reported biologic (23.1%), followed by secukinumab (15.7%) and dupilumab (13.2%)...Adverse events were reported in one patient receiving efalizumab. Biologic therapies represent a promising advancement in LP management, providing targeted treatment options with potential for favorable outcomes. Future research should focus on validating these findings through larger studies and assessing long-term safety and effectiveness."

Review • Dermatology • Dermatopathology • Lichen Planus

PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab. (PubMed, Front Pharmacol) - "In this project, we compared the pharmacokinetics of a therapeutic protein in rabbit, NHP and human using an open PBPK modeling platform (Open Systems Pharmacology Suite, http://www.open-systems-pharmacology.org). Our findings could support similar translatory studies for first in human dose predictions in the future."

Journal • Preclinical

Guselkumab-associated bullous pemhigoid in a psoriasis patient: A case report. (EADV 2024) - "This case shows the rare side effect of the development of DBP in a patient being treated with guselkumab."

Case report • Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A

Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review. (PubMed, J Asthma Allergy) - "Omalizumab reduced AHR to methacholine, acetylcholine or adenosine monophosphate (3/9 studies), and reduced EAR (4/5 studies) and LAR (2/3 studies). Mepolizumab had no effect on AHR (3/3 studies), EAR or LAR (1/1 study)...Pitrakinra reduced LAR, with no effect on AHR (1/1 study). Etanercept reduced AHR to methacholine (1/2 studies). No effects were observed for lebrikizumab, tocilizumab, efalizumab, IMA-638 and anti-OX40 ligand on AHR, EAR or LAR; benralizumab on LAR; tralokinumab on AHR; and Ro-24-7472 on AHR or LAR (all 1/1 study each). No dupilumab or reslizumab studies were identified...These findings provide insights into AHR mechanisms and the precise effects of asthma biologics. Furthermore, findings suggest that tezepelumab broadly targets allergen-specific and non-allergic forms of AHR, and the underlying cells and mediators involved in asthma."

Journal • Review • Allergy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes. (PubMed, Transpl Int) - "Ten consecutive non-uremic patients with Type 1 diabetes underwent islet transplant with immunosuppression based on belatacept (BELA; n = 5) or efalizumab (EFA; n = 5). In our series, repeat islet transplant is ineffective at maintaining long-term insulin independence. PAI results in durable insulin independence but is associated with impaired renal function secondary to CNI dependence."

Journal • Diabetes • Hepatology • Metabolic Disorders • Transplantation • Type 1 Diabetes Mellitus

Review of natural compounds for potential psoriasis treatment. (PubMed, Inflammopharmacology) - "Alefacept, efalizumab, Adalimumab, Ustekinumab, and Secukinumab are a few examples of chemical drugs. Its rapidly progressive infection of the central nervous system caused by the JC virus and other drugs may cause increased production of neutralising anti-drug antibodies (ADA) and the risk of infusion reactions like pruritus, flushing, hypertension, headache, and rash. So, our context intends to talk in our review about natural products or plants that may have therapeutic characteristics for this disease and may have few or no side effects on the patient's body."

Journal • Review • Cardiovascular • CNS Disorders • Dermatology • Hypertension • Immunology • Infectious Disease • Inflammation • Pain • Pruritus • Psoriasis • Rare Diseases • IL12A • IL17A • IL23A

Different Treatment Modalities of Oral Lichen Planus-A Narrative Review. (PubMed, Dent J (Basel)) - "Some of the therapies mentioned are tacrolimus, efalizumab, dapson, interferon, retinoic acid, photochemotherapy with psoralen and ultraviolet A rays (PUVA), aloe vera, antimalarials, antibiotics and others. These therapies only partially meet the properties of efficacy and safety of use, thus justifying the continuous search and testing of new treatment methods."

Journal • Review • Dermatology • Dermatopathology • Infectious Disease • Inflammation • Lichen Planus • Pain

Toward Systems-Informed Models for Biologics Disposition: Covariates of the Abundance of the Neonatal Fc Receptor (FcRn) in Human Tissues and Implications for Pharmacokinetic Modelling. (PubMed, Eur J Pharm Sci) - "FcRn mRNA in plasma-derived exosomes correlated moderately with protein abundance in matching liver tissue, opening the possibility of use as a potential clinical tool. Predicted effects of trends in FcRn abundance in healthy and disease (cancer and psoriasis) populations using trastuzumab and efalizumab PBPK models were in line with clinical observations, and global sensitivity analysis revealed endogenous IgG plasma concentration and tissue FcRn abundance as key systems parameters influencing exposure to Fc-conjugated biologics."

Journal • PK/PD data • Dermatology • Immunology • Oncology • Psoriasis • B2M

Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review. (PubMed, J Neurol Sci) - "In fact, PML has been witnessed with several mAbs, including natalizumab in multiple sclerosis, rituximab for lymphoma or lupus, efalizumab for psoriasis, and ofatumumab in leukemia; this leads us to the risk reassessment of PML due to treatment-induced immunosuppression...This article aims to review the relationship between the incidence of PML and all four mAbs used in the treatment of MS. Currently, at least 18 FDA-approved medications carry label warnings for PML;to this date, no treatment has been convincingly effective."

Journal • Review • CNS Disorders • Dermatology • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Leukemia • Lupus • Lymphoma • Multiple Sclerosis • Oncology • Psoriasis • Rare Diseases

Biologic-induced photosensitivity: a case of three (BAD 2022) - "Dupilumab and secukinumab target moderate-to-severe atopic dermatitis and plaque psoriasis, respectively...In the autumn months, dupilumab was stopped owing to worsening of the rash despite sun protection and managing her rosacea with brimonidine...Furthermore, the patient had not reported photosensitivity on previous biologics: etanercept, adalimumab, infliximab, efalizumab and ustekinumab...Bloods and autoimmune screen were unremarkable. The patient is reluctant to stop vedolizumab as it is the only biologic that controls her UC."

Clinical • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology • Pain • Pediatrics • Pruritus • Psoriasis • Psoriatic Arthritis • Rheumatology • Rosacea • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL13 • IL17A

Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. (PubMed, J Dermatolog Treat) - "These cases implicated two cases induced by adalimumab, three by efalizumab, three by etanercept, six by ustekinumab, and one case by secukinumab. A close monitoring of skin condition is highly advisable in patients receiving biologic therapies for psoriasis. Knowledge of BIBP is of great importance to determine the preventive measures and select optimal treatment options."

Journal • Review • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Psoriasis

Effect of Biologics on Allergic Response and Airway Hyperresponsiveness: A Systematic Literature Review (ATS 2022) - "Mepolizumab had no effect on EAR or LAR (1/1 study) or AHR (3/3 studies). In one study each, IMA-638, lebrikizumab and tralokinumab had no effect on AHR. Pitrakinra reduced LAR, with no effect on AHR (1/1 study). Etanercept reduced AHR in one study. Benralizumab had no effect on LAR (1/1 study), and no studies were identified assessing AHR. In one study each, efalizumab, tocilizumab, Ro-24-7472 and anti-OX40 ligand had no effect on AHR...No published studies were identified for dupilumab or reslizumab.CONCLUSIONSAcross multiple biologics studied, reductions in both EAR and LAR to allergens were observed with omalizumab and tezepelumab. Tezepelumab also consistently attenuated nonspecific AHR to methacholine or mannitol. These findings provide further insight into the mechanisms of AHR and the clinical benefits of asthma biologics and suggest that tezepelumab may broadly target mediators or cells involved in asthma inflammation."

Review • Allergy • Asthma • Inflammation • Pulmonary Disease • Respiratory Diseases

Long-Term Insulin Independence Achieved by a Multimodal Approach to Beta-Cell Replacement in Patients with Type I Diabetes (ATC 2022) - "Here, we report a multimodal approach including islet and pancreas after islet (PAI) transplant utilizing CNI-free immunosuppression (IS) regimens based on Belatacept (BELA) and Efalizumab (EFA). Our results describe a multi-modal, personalized approach to beta-cell replacement in T1D. In our series, repeat islet transplant is ineffective at restoring insulin independence. PAI results in durable insulin independence but was associated with impaired renal function in 1/3 of recipients secondary to CNI dependence."

Clinical • Diabetes • Hepatology • Immunology • Metabolic Disorders • Transplantation • Type 1 Diabetes Mellitus • CD4 • FOXP3

Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis. (PubMed, Medicine (Baltimore)) - "We analyzed the properties of the miRNA-regulated drug-pathway network through genes and uncovered a number of novel MS agents by assessing their respective Z-values.A total of 20 likely drug candidates were identified, including human immunoglobulin, aspirin, alemtuzumab, minocycline, abciximab, alefacept, palivizumab, bevacizumab, efalizumab, tositumomab, minocycline, etanercept, catumaxomab, and sarilumab. Each of these agents were then explored with regards to their likely mechanism of action in treating MS.The current investigation provides a fresh perspective on MS biological mechanisms as well as likely treatment strategies."

Journal • CNS Disorders • Multiple Sclerosis

Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago. (PubMed, Dermatol Ther (Heidelb)) - "This study in the real-world-setting shows maintenance of long-term efficacy and safety of biologic therapy in patients with moderate to severe plaque psoriasis in daily practice who initiated biologic therapy 10 years ago."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses. (PubMed, Front Mol Neurosci) - "Hub gene-drug interaction analysis found four drugs (maraviroc, cenicriviroc, PF-04634817, and efalizumab) that could be potential drugs for VaD treatment. Together, our results may contribute to understanding the underlying mechanisms in VaD and provide potential targets and drugs for therapeutic intervention."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Immunology • Inflammation • CD163 • CREB1 • FOXC1 • GATA2 • MIR129 • MIR129-2 • MIR146A • MIR27A • MIR335

Review of Current and Novel Treatment Pathways to Manage Plaque Psoriasis - Episode 14: Incorporating New Therapeutic Agents into Plaque Psoriasis Therapy (HCPLive) - "Mark Lebwohl, MD: I already have large lists of patients who we are ready to treat with bimekizumab, deucravacitinib, and the 2 new nonsteroidal topical agents that we discussed. And as soon as they're approved, we have email addresses to let patients know that those drugs are available....Leon H. Kircik, MD: I usually am. That's because I am biased because I've done most of those studies, and I have those patients already on extension or the long-label safety treatments. I see how they're doing, I'm exposed to the drug before it comes to the market. I'm lucky from that perspective....Jerry Bagel, MD, MS:Absolutely. In many ways, these are 2 of the biggest changes that we’ve had at least since the beginning of IL-17s [interleukin-17 inhibitors], which was 6 years ago. A pill that can work two-thirds of the time, people are going to jump on that."

Video

Guselkumab-associated bullous pemphigoid in a psoriasis patient: a case report and review of the literature. (PubMed, Dermatol Ther) - "Up to date, DBP has been described after biological therapy for psoriasis in 11 patients, following administration of ustekinumab, efalizumab, etanercept, secukinumab and adalimumab. Conversely, DBP after guselkumab therapy for psoriasis has never been reported in published studies. We highlight the need to face and document increasing, though rare, side effects of biologic therapies, as new biologic molecules are being constantly developed and administered to psoriatic patients, to promptly interrupt treatment when needed."

Clinical • Journal • Review • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Psoriasis • IL12A

Risankizumab-induced rosacea-like dermatitis (ISDS 2021) - "She had already been treated with phototherapy, methotrexate, cyclosporine, efalizumab 15-year before and was currently using only high-potency topical corticosteroids...It was precribed a single dose of ivermectin, fexofenadine for 7 days, topical 0.75 metronidazole for 3 months, fexofenadine for 7 days and photoprotection...Although there are less common possible triggering factors, the aim of this case is to presente the current knowledge on the association between of certain drugs and rosacea. Moreover, risankizumab improved health-related quality of life for psoriasis control and was generally well tolerated."

Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammatory Arthritis • Pruritus • Psoriasis • Psoriatic Arthritis • Rheumatology • Rosacea • Seronegative Spondyloarthropathies